Crinetics (CRNX)’ treatment of congenital adrenal hyperplasia, generic name atumelnant, was granted FDA orphan designation, according to a post to the agency’s site.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharma’s Earnings Call: Progress Amid Challenges
- Crinetics Pharmaceuticals: A Promising Buy with Strategic Initiatives and Upcoming Milestones
- Crinetics price target lowered to $86 from $90 at Citizens JMP
- Crinetics Pharmaceuticals Reports Q2 2025 Financial Results
- Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch